Abstract
Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons
Current Vascular Pharmacology
Title: “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
Volume: 9 Issue: 5
Author(s): Klaus G. Parhofer, Evangelos Liberopoulos, Matilda Florentin, Karl Winkler, Anthony S. Wierzbicki, Alexandros D. Tselepis, Gerald H. Tomkin, Giatgen A. Spinas, Giovam Battista Rini, Dimitri P. Mikhailidis, Winfried Marz, Jacqueline de Graaf, Vasilios Athyros, Alberto Zambon, Bruce Griffin, Kaspar Berneis, Manfredi Rizzo and Moses Elisaf
Affiliation:
Keywords: LDL, subclasses, atherosclerosis, cardiovascular risk, statement, hypertriglyceridaemia, coronary heart disease, cardiovascular disease, apolipoprotein, chylomicrons
Abstract: Aim of the present Consensus Statement is to provide a comprehensive and up to-date document on the pathophysiology, atherogenicity and clinical significance of low density lipoproteins (LDL) subclasses. We sub-divided our Statement in 2 sections: section I discusses the pathophysiology, atherogenicity and measurement issues, while section II is focused on the effects of drugs and lifestlyle modifications. Suggestions for future research in the field are highlighted at the end of section II. Each section includes Conclusions.
Export Options
About this article
Cite this article as:
G. Parhofer Klaus, Liberopoulos Evangelos, Florentin Matilda, Winkler Karl, S. Wierzbicki Anthony, D. Tselepis Alexandros, H. Tomkin Gerald, A. Spinas Giatgen, Battista Rini Giovam, P. Mikhailidis Dimitri, Marz Winfried, de Graaf Jacqueline, Athyros Vasilios, Zambon Alberto, Griffin Bruce, Berneis Kaspar, Rizzo Manfredi and Elisaf Moses, “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses, Current Vascular Pharmacology 2011; 9 (5) . https://dx.doi.org/10.2174/157016111796642661
DOI https://dx.doi.org/10.2174/157016111796642661 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Synthesis of New 1-Substituted-1H-1,2,3,4-Tetrazoles from L-α-Amino Acids and Their Biological Assays
Letters in Organic Chemistry Management of COVID-19 very Elderly Patients in Nursing Homes and Long-Term Care Facilities: Description of a New Model and Experience in a Medicalized Nursing Home
Coronaviruses Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Targeting Mitochondria for Cardiac Protection
Current Drug Targets Oxidative Stress in the Cochlea: An Update
Current Medicinal Chemistry The Effect of TNFα-Inhibitors on Cardiovascular Events in Patients with Rheumatoid Arthritis: An Updated Systematic Review of the Literature
Current Rheumatology Reviews Physical Exercise and ACE2-Angiotensin-(1-7)-Mas Receptor Axis of the Renin Angiotensin System
Protein & Peptide Letters Boundaries and Overlap between Hypochondriasis and Other Disorders: Differential Diagnosis and Patterns of Co-occurrence
Current Psychiatry Reviews Cell-Based Therapy to Promote Angiogenesis in the Brain Following Ischemic Damage
Current Vascular Pharmacology Frailty Among Alzheimer’s Disease Patients
CNS & Neurological Disorders - Drug Targets Molecular Basis of Cardioprotection by Erythropoietin
Current Molecular Pharmacology Non-pharmacological Strategies Against Systemic Inflammation: Molecular Basis and Clinical Evidence
Current Pharmaceutical Design Interactions Between Plasma Proteins and Naturally Occurring Polyphenols
Current Drug Metabolism A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Adverse Effects of Statins - Mechanisms and Consequences
Current Drug Safety Editorial [Hot Topic Cells, Micro- and Nanosystems in Reconstructive Medicine: Past, Present, and Future Guest Editors: Christian Andressen & Andreas Wree]
Current Pharmaceutical Biotechnology Non Invasive Indexes for the Assessment of Patients with Non-alcoholic Fatty Liver Disease
Current Pharmaceutical Design Protein Kinase C – Possible Therapeutic Target to Treat Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets